RU2225615C2 - Способ дифференциации между наличием риска образования язвы желудка и язвы двенадцатиперстной кишки - Google Patents
Способ дифференциации между наличием риска образования язвы желудка и язвы двенадцатиперстной кишки Download PDFInfo
- Publication number
- RU2225615C2 RU2225615C2 RU2001132335/15A RU2001132335A RU2225615C2 RU 2225615 C2 RU2225615 C2 RU 2225615C2 RU 2001132335/15 A RU2001132335/15 A RU 2001132335/15A RU 2001132335 A RU2001132335 A RU 2001132335A RU 2225615 C2 RU2225615 C2 RU 2225615C2
- Authority
- RU
- Russia
- Prior art keywords
- gastrin
- pepsinogen
- concentration
- risk
- serum
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 9
- 208000000718 duodenal ulcer Diseases 0.000 title claims abstract description 8
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 7
- 230000004069 differentiation Effects 0.000 title abstract 2
- 102400000921 Gastrin Human genes 0.000 claims abstract description 48
- 108010066264 gastrin 17 Proteins 0.000 claims abstract description 35
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 claims abstract description 35
- 108010047320 Pepsinogen A Proteins 0.000 claims abstract description 34
- 210000002966 serum Anatomy 0.000 claims abstract description 33
- 239000000126 substance Substances 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 241000590002 Helicobacter pylori Species 0.000 claims description 7
- 229940037467 helicobacter pylori Drugs 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000004020 luminiscence type Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 abstract description 12
- 208000011906 peptic ulcer disease Diseases 0.000 abstract description 11
- 238000011161 development Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000004807 localization Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 description 34
- 210000002784 stomach Anatomy 0.000 description 24
- 108010052343 Gastrins Proteins 0.000 description 17
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 17
- 206010003694 Atrophy Diseases 0.000 description 14
- 230000037444 atrophy Effects 0.000 description 14
- 208000023652 chronic gastritis Diseases 0.000 description 10
- 208000004300 Atrophic Gastritis Diseases 0.000 description 8
- 208000036495 Gastritis atrophic Diseases 0.000 description 8
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 5
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 101800000285 Big gastrin Proteins 0.000 description 3
- 102400000948 Big gastrin Human genes 0.000 description 3
- 108090001072 Gastricsin Proteins 0.000 description 3
- 102000034255 Pepsinogen C Human genes 0.000 description 3
- 108010014475 Pepsinogens Proteins 0.000 description 3
- 102000023022 Pepsinogens Human genes 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- FMIHGWZLPSIAFY-WGFKALLTSA-N gastrin-34 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C1=CC=C(O)C=C1 FMIHGWZLPSIAFY-WGFKALLTSA-N 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000746 body region Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000020459 Anaemia of malignant disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010054272 Helicobacter gastritis Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 238000008330 Pyloriset EIA-G Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000465 brunner gland Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- SSBRJDBGIVUNDK-QOGDCIHTSA-N gastrin-14 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSBRJDBGIVUNDK-QOGDCIHTSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 108010076432 minigastrin Proteins 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/062—Gastritis or peptic ulcer disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Seal Device For Vehicle (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI990992A FI118653B (fi) | 1999-04-30 | 1999-04-30 | Menetelmä peptisen haavan riskin määrittämiseksi |
| FI990992 | 1999-04-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2001132335A RU2001132335A (ru) | 2003-08-27 |
| RU2225615C2 true RU2225615C2 (ru) | 2004-03-10 |
Family
ID=8554567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001132335/15A RU2225615C2 (ru) | 1999-04-30 | 2000-04-28 | Способ дифференциации между наличием риска образования язвы желудка и язвы двенадцатиперстной кишки |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6872543B1 (enExample) |
| EP (1) | EP1173770B1 (enExample) |
| JP (1) | JP4598959B2 (enExample) |
| CN (1) | CN100573152C (enExample) |
| AT (1) | ATE300053T1 (enExample) |
| AU (1) | AU4299800A (enExample) |
| DE (1) | DE60021369T2 (enExample) |
| DK (1) | DK1173770T3 (enExample) |
| ES (1) | ES2241597T3 (enExample) |
| FI (1) | FI118653B (enExample) |
| PT (1) | PT1173770E (enExample) |
| RU (1) | RU2225615C2 (enExample) |
| WO (1) | WO2000067035A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA021520B1 (ru) * | 2011-04-08 | 2015-07-30 | Сергей Михайлович Котелевец | Способ определения вероятности развития рака желудка |
| RU2582565C1 (ru) * | 2015-03-06 | 2016-04-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации /ГБОУ ВПО ОрГМУ Минздрава России/ | Способ дифференциальной диагностики язвы желудка и двенадцатиперстной кишки |
| RU2677228C1 (ru) * | 2017-12-08 | 2019-01-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" | Способ иммунодиагностики заболеваний гастродуоденальной зоны |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20010019A7 (fi) | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen gastriitin diagnostisoimiseksi |
| AU2002252456A1 (en) * | 2001-03-23 | 2002-10-08 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| EP1416964A4 (en) * | 2001-07-09 | 2005-10-12 | Aphton Corp | TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS DISEASES OF THE LIVER, LUNG AND ESOPHAGUS |
| SE0200974D0 (sv) * | 2002-03-27 | 2002-03-27 | Phagen Ab | Screening method for gastritis |
| FI119571B (fi) * | 2002-09-06 | 2008-12-31 | Biohit Oyj | Menetelmä esofagiitin tai Barrettin ruokatorven riskin osoittamiseksi yksilöllä |
| EP1608984A2 (en) * | 2003-03-28 | 2005-12-28 | Aphton Corporation | Gastrin hormone immunoassays |
| US20060020119A1 (en) * | 2004-03-29 | 2006-01-26 | Stephen Grimes | Monoclonal antibodies to gastrin hormone |
| FI119572B (fi) * | 2004-03-05 | 2008-12-31 | Biohit Oyj | Menetelmä vatsan limakalvon tilan ennustamiseksi |
| US8158128B2 (en) | 2004-09-22 | 2012-04-17 | Cancer Advances, Inc. | Monoclonal antibodies to progastrin |
| US8272265B2 (en) * | 2005-07-12 | 2012-09-25 | Technion Research And Development Foundation Ltd. | System and method for active detection of asymmetry in rotating structures |
| EP2203745A4 (en) * | 2007-10-26 | 2010-12-08 | Biohit Oyj | METHODS AND PRODUCTS FOR DIAGNOSING AUTOIMMUNE DISEASES AND GASTRIC CANCER RELATED TO ATROPHIC GASTRITIS |
| CN104820096B (zh) * | 2015-04-30 | 2017-04-19 | 必欧瀚生物技术（合肥）有限公司 | 一种判断早期胃癌风险检测用标志物的量的联合标准量及在筛查早期胃癌方面的应用 |
| CN107271669A (zh) * | 2016-09-23 | 2017-10-20 | 清华大学深圳研究生院 | 胃蛋白酶原、抗幽门螺杆菌抗体和胃泌素17检测方法及其试剂盒 |
| CN107328938A (zh) * | 2016-09-23 | 2017-11-07 | 清华大学深圳研究生院 | 胃蛋白酶原和抗幽门螺杆菌抗体检测方法及其试剂盒 |
| JP6885581B2 (ja) * | 2017-02-06 | 2021-06-16 | 学校法人東京歯科大学 | ガストリン測定におけるカットオフ値の推定方法 |
| CA3066756A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07304800A (ja) * | 1994-05-06 | 1995-11-21 | Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk | ヒトペプシノゲンに対するモノクローナル抗体 |
| FI97304C (fi) * | 1994-11-16 | 1996-11-25 | Locus Genex Oy | Menetelmä mahasyövän riskin seulonnaksi |
| JP2949474B2 (ja) * | 1995-08-28 | 1999-09-13 | 隆久 古田 | ペプシノーゲンｉ／ｉｉ比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法 |
| JPH10148636A (ja) * | 1996-11-15 | 1998-06-02 | Takahisa Furuta | ペプシノーゲン ｉ／ｉｉ 比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法 |
-
1999
- 1999-04-30 FI FI990992A patent/FI118653B/fi active IP Right Grant
-
2000
- 2000-04-28 EP EP00922684A patent/EP1173770B1/en not_active Expired - Lifetime
- 2000-04-28 DE DE60021369T patent/DE60021369T2/de not_active Expired - Lifetime
- 2000-04-28 US US09/959,551 patent/US6872543B1/en not_active Expired - Lifetime
- 2000-04-28 CN CN00808720.2A patent/CN100573152C/zh not_active Expired - Lifetime
- 2000-04-28 PT PT00922684T patent/PT1173770E/pt unknown
- 2000-04-28 RU RU2001132335/15A patent/RU2225615C2/ru active
- 2000-04-28 ES ES00922684T patent/ES2241597T3/es not_active Expired - Lifetime
- 2000-04-28 DK DK00922684T patent/DK1173770T3/da active
- 2000-04-28 AU AU42998/00A patent/AU4299800A/en not_active Abandoned
- 2000-04-28 AT AT00922684T patent/ATE300053T1/de not_active IP Right Cessation
- 2000-04-28 JP JP2000615822A patent/JP4598959B2/ja not_active Expired - Lifetime
- 2000-04-28 WO PCT/FI2000/000377 patent/WO2000067035A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| ЕЛИЗАВЕТИНА Г.А. и др. Комплексная оценка диагностических показателей агрессивных и защитных факторов у больных пилородуоденитом. Эффективность внедрения новых методов профилактики, диагностики и лечения в клинической медицине. Сб. науч. тр. - М., 1990, с.50-54. ВАЛЕНКЕВИЧ Л.Н. Содержание гастрина и пепсиногена у больных хроническим атрофическим гастритом и язвой двенадцатиперстной кишки. Врачебное дело, 1993, № 2 и 3, с.56-58. Клиническая оценка лабораторных тестов. - М.: Медицина, 1986, с.119 и 120. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA021520B1 (ru) * | 2011-04-08 | 2015-07-30 | Сергей Михайлович Котелевец | Способ определения вероятности развития рака желудка |
| RU2582565C1 (ru) * | 2015-03-06 | 2016-04-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации /ГБОУ ВПО ОрГМУ Минздрава России/ | Способ дифференциальной диагностики язвы желудка и двенадцатиперстной кишки |
| RU2677228C1 (ru) * | 2017-12-08 | 2019-01-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" | Способ иммунодиагностики заболеваний гастродуоденальной зоны |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100573152C (zh) | 2009-12-23 |
| EP1173770A1 (en) | 2002-01-23 |
| DE60021369T2 (de) | 2006-05-24 |
| WO2000067035A1 (en) | 2000-11-09 |
| EP1173770B1 (en) | 2005-07-20 |
| DE60021369D1 (de) | 2005-08-25 |
| AU4299800A (en) | 2000-11-17 |
| ES2241597T3 (es) | 2005-11-01 |
| CN1355888A (zh) | 2002-06-26 |
| FI990992A0 (fi) | 1999-04-30 |
| JP2002543433A (ja) | 2002-12-17 |
| FI990992L (fi) | 2000-10-31 |
| PT1173770E (pt) | 2005-09-30 |
| DK1173770T3 (da) | 2005-08-08 |
| US6872543B1 (en) | 2005-03-29 |
| FI118653B (fi) | 2008-01-31 |
| JP4598959B2 (ja) | 2010-12-15 |
| ATE300053T1 (de) | 2005-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2225615C2 (ru) | Способ дифференциации между наличием риска образования язвы желудка и язвы двенадцатиперстной кишки | |
| US7358062B2 (en) | Method for diagnosing atrophic gastritis | |
| Karnes Jr et al. | Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis | |
| US20010039025A1 (en) | Method for screening the risk of gastric cancer | |
| Johnston et al. | Preliminary results from follow‐up of a large‐scale population survey of antibodies to gliadin, reticulin and endomysium | |
| US20070178442A1 (en) | Method for diagnosing liver fibrosis | |
| EP1552311B1 (en) | Method for detecting a risk of acid related disease in an individual | |
| DE69319240T2 (de) | In vitro-test für helicobacter pylori | |
| JP4820192B2 (ja) | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 | |
| EP1725876B1 (en) | A method for predicting the state of the gastric mucosa | |
| US7179609B1 (en) | Screening method for gastritis | |
| US4558004A (en) | Monitoring preneoplastic antigen | |
| US20040038329A1 (en) | Methods for monitoring treatment of helicobacter infection and for predicting the likelihood of successful eradication | |
| EP1488238B1 (en) | Screening method for gastritis | |
| Ventrucci | Update on laboratory diagnosis and prognosis of acute pancreatitis | |
| Oksanen et al. | Serologic diagnosis of Helicobacter pylori infection in outpatients aged 45 years or less | |
| RU2197736C1 (ru) | Реагент для иммуноферментного анализа и способ иммуноферментного тестирования специфических антител при описторхозе, вызываемом печеночной трематодой opisthorhis felineus | |
| HK1081652A (en) | Method for detecting a risk of acid related disease in an individual | |
| AU2001268835A1 (en) | Methods for monitoring treatment of helicobacter infection and for predicting the likelihood of successful eradication |